[Patient-reported outcome and its application in hematological neoplasm].
作者信息
Jiang Q
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):614-619. doi: 10.3760/cma.j.issn.0253-2727.2019.07.019.
Abstract
摘要
相似文献
1
[Patient-reported outcome and its application in hematological neoplasm].
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):614-619. doi: 10.3760/cma.j.issn.0253-2727.2019.07.019.
2
Using patient-reported outcomes to improve survivorship care.
Blood. 2020 May 21;135(21):1819-1820. doi: 10.1182/blood.2020005881.
3
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
J Comp Eff Res. 2019 May;8(7):523-533. doi: 10.2217/cer-2018-0108. Epub 2019 Apr 30.
4
Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review.
JAMA Netw Open. 2024 Jun 3;7(6):e2414425. doi: 10.1001/jamanetworkopen.2024.14425.
5
Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
Saudi Med J. 2003 Feb;24(2):138-41.
6
Diagnostic application of FISH to hematological malignancies.
Cancer Invest. 2003;21(5):807-14. doi: 10.1081/cnv-120023780.
7
Important questions for the malignant hematologist to consider when designing or evaluating a study with patient-reported outcome measures (PROMs).
Eur J Haematol. 2022 Jul;109(1):3-9. doi: 10.1111/ejh.13774. Epub 2022 Apr 29.
8
Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Transplant Cell Ther. 2021 May;27(5):390.e1-390.e7. doi: 10.1016/j.jtct.2021.01.003. Epub 2021 Jan 7.
9
Patient-reported distress and problems among elderly patients with hematological malignancy in Korea.
Support Care Cancer. 2022 Nov;30(11):9019-9027. doi: 10.1007/s00520-022-07315-9. Epub 2022 Aug 10.
10
Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies.
Lancet Oncol. 2019 Dec;20(12):1625-1626. doi: 10.1016/S1470-2045(19)30641-2. Epub 2019 Oct 9.
引用本文的文献
1
[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217.
2
[Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):54-61. doi: 10.3760/cma.j.cn121090-20231008-00162.
本文引用的文献
1
Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia.
Oncotarget. 2018 Jul 27;9(58):31244-31252. doi: 10.18632/oncotarget.25787.
2
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.
BMC Cancer. 2018 Aug 3;18(1):782. doi: 10.1186/s12885-018-4699-5.
3
Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
J Cancer Res Clin Oncol. 2018 Apr;144(4):735-741. doi: 10.1007/s00432-018-2594-8. Epub 2018 Jan 29.
4
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
J Cancer Res Clin Oncol. 2017 Dec;143(12):2619-2630. doi: 10.1007/s00432-017-2517-0. Epub 2017 Sep 11.
5
Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?
Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10.
6
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
J Cancer Res Clin Oncol. 2017 Jun;143(6):1013-1022. doi: 10.1007/s00432-017-2353-2. Epub 2017 Mar 1.
7
Health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence.
Qual Life Res. 2017 May;26(5):1371-1377. doi: 10.1007/s11136-016-1462-8. Epub 2016 Nov 24.
8
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.
9
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.
Eur J Haematol. 2016 Nov;97(5):416-429. doi: 10.1111/ejh.12790. Epub 2016 Sep 6.
10
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
Acta Oncol. 2016 Sep-Oct;55(9-10):1115-1120. doi: 10.1080/0284186X.2016.1205217. Epub 2016 Aug 5.
Zotero 插件